Characteristics of the study population
| Variable . | n (%) N = 240 . |
|---|---|
| Sex | |
| Female | 108 (45) |
| Male | 132 (55) |
| Race | |
| White | 185 (78) |
| Other | 52 (22) |
| Diagnosis | |
| MDS | 114 (47) |
| AML | 126 (53) |
| Cytogenetics | |
| Complex | 171 (71) |
| 5q/7q | 18 (8) |
| Other | 44 (18) |
| Missing | 7 (3) |
| TP53 allele status | |
| Monohit | 66 (28) |
| Multihit | 166 (69) |
| Missing | 8 (3) |
| VAF, median (range) [IQRT] | 28.21 (1.02-98.5) [9.1-48.55] |
| Missing | 16 (7) |
| EA score, median (range) [IQRT] | 84.11 (3.4-100) [72.52-95.2] |
| Missing | 17 (7) |
| TP53 detected pre-TP in CR | |
| Yes | 46 (49) |
| No | 22 (23) |
| N/A | 26 (28) |
| Number of TP53 mutations | |
| 1 | 169 (70) |
| 2 | 57 (24) |
| >2 | 14 (6) |
| Diagnosis to transplant, (range) [IQRT], mo | 6.5 (0.3-319) [4.6-10.5] |
| Prior disease treatment, median (range) [IQRT] | 1 (0-6) [1-2] |
| Prior disease treatment | |
| HMA alone | 110 (45) |
| HMA and chemotherapy | 34 (14) |
| HMA and venetoclax | 33 (14) |
| HMA and chemotherapy and venetoclax | 18 (6) |
| Chemotherapy alone | 29 (12) |
| Chemotherapy and venetoclax | 11 (4) |
| Others | 1 (0.4) |
| None | 4 (1.6) |
| Age at TP, median (range) [IQRT] | 62 (18-75), 34 [56-67] |
| Donor age, median (range) [IQRT] | 36 (6-72) [27-52] |
| HCT-CI, median (range) [IQRT] | 4 (0-10) [2-5] |
| Donor type | |
| MRD | 61 (25) |
| MUD | 126 (53) |
| Haplo | 42 (17) |
| MMUD | 11 (5) |
| Conditioning intensity | |
| Reduced intensity | 99 (41) |
| Melphalan based | 88 |
| Busulfan based | 11 |
| Myeloablative/all busulfan based | 141 (59) |
| GVHD prophylaxis | |
| PTCy | 1 (0.4) |
| PTCy/TAC | 39 (16.2) |
| PTCy/TAC/MMF | 119 (49.6) |
| TAC/MTX | 81 (33.8) |
| Therapy-related AML | |
| Yes | 40 (32) |
| No | 86 (68) |
| Disease status at transplant | |
| CR1 | 91 (38) |
| CR2 | 2 (0.8) |
| CR3 | 1 (0.4) |
| Primary induction failure | 128 (53) |
| First relapse | 14 (6) |
| Untreated | 4 (2) |
| Donor/recipient CMV serostatus | |
| R/R | 100 (42) |
| R/NR | 23 (10) |
| NR/R | 88 (36) |
| NR/NR | 29 (12) |
| Stem cell source | |
| MSD: | |
| PB | 60 (98) |
| MUD: | |
| PB | 86 (68) |
| BM | 40 (32) |
| Haplo: | |
| PB | 13 (31) |
| BM | 29 (69) |
| MMUD: | |
| PB | 7 (64) |
| BM | 4 (36) |
| Follow-up in surviving patients, median (range) [IQRT] | 19 (3.26-93) [10-37.76] |
| Variable . | n (%) N = 240 . |
|---|---|
| Sex | |
| Female | 108 (45) |
| Male | 132 (55) |
| Race | |
| White | 185 (78) |
| Other | 52 (22) |
| Diagnosis | |
| MDS | 114 (47) |
| AML | 126 (53) |
| Cytogenetics | |
| Complex | 171 (71) |
| 5q/7q | 18 (8) |
| Other | 44 (18) |
| Missing | 7 (3) |
| TP53 allele status | |
| Monohit | 66 (28) |
| Multihit | 166 (69) |
| Missing | 8 (3) |
| VAF, median (range) [IQRT] | 28.21 (1.02-98.5) [9.1-48.55] |
| Missing | 16 (7) |
| EA score, median (range) [IQRT] | 84.11 (3.4-100) [72.52-95.2] |
| Missing | 17 (7) |
| TP53 detected pre-TP in CR | |
| Yes | 46 (49) |
| No | 22 (23) |
| N/A | 26 (28) |
| Number of TP53 mutations | |
| 1 | 169 (70) |
| 2 | 57 (24) |
| >2 | 14 (6) |
| Diagnosis to transplant, (range) [IQRT], mo | 6.5 (0.3-319) [4.6-10.5] |
| Prior disease treatment, median (range) [IQRT] | 1 (0-6) [1-2] |
| Prior disease treatment | |
| HMA alone | 110 (45) |
| HMA and chemotherapy | 34 (14) |
| HMA and venetoclax | 33 (14) |
| HMA and chemotherapy and venetoclax | 18 (6) |
| Chemotherapy alone | 29 (12) |
| Chemotherapy and venetoclax | 11 (4) |
| Others | 1 (0.4) |
| None | 4 (1.6) |
| Age at TP, median (range) [IQRT] | 62 (18-75), 34 [56-67] |
| Donor age, median (range) [IQRT] | 36 (6-72) [27-52] |
| HCT-CI, median (range) [IQRT] | 4 (0-10) [2-5] |
| Donor type | |
| MRD | 61 (25) |
| MUD | 126 (53) |
| Haplo | 42 (17) |
| MMUD | 11 (5) |
| Conditioning intensity | |
| Reduced intensity | 99 (41) |
| Melphalan based | 88 |
| Busulfan based | 11 |
| Myeloablative/all busulfan based | 141 (59) |
| GVHD prophylaxis | |
| PTCy | 1 (0.4) |
| PTCy/TAC | 39 (16.2) |
| PTCy/TAC/MMF | 119 (49.6) |
| TAC/MTX | 81 (33.8) |
| Therapy-related AML | |
| Yes | 40 (32) |
| No | 86 (68) |
| Disease status at transplant | |
| CR1 | 91 (38) |
| CR2 | 2 (0.8) |
| CR3 | 1 (0.4) |
| Primary induction failure | 128 (53) |
| First relapse | 14 (6) |
| Untreated | 4 (2) |
| Donor/recipient CMV serostatus | |
| R/R | 100 (42) |
| R/NR | 23 (10) |
| NR/R | 88 (36) |
| NR/NR | 29 (12) |
| Stem cell source | |
| MSD: | |
| PB | 60 (98) |
| MUD: | |
| PB | 86 (68) |
| BM | 40 (32) |
| Haplo: | |
| PB | 13 (31) |
| BM | 29 (69) |
| MMUD: | |
| PB | 7 (64) |
| BM | 4 (36) |
| Follow-up in surviving patients, median (range) [IQRT] | 19 (3.26-93) [10-37.76] |
BM, bone marrow; CMV, cytomegalovirus Haplo, haploidentical; HCT-CI, hematopoietic cell transplantation–comorbidity index; IQRT, interquartile range; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MSD, matched sibling donor; MTX, methotrexate; MUD, matched unrelated donor; NA, non-applicable; NR, nonreactive; PB, peripheral blood; PTCy, posttransplant cyclophosphamide; R, reactive; TAC, tacrolimus; TP, transplant.